过敏性炎症细胞在冠状动脉疾病中的作用
本综述探讨过敏性炎症效应细胞在冠状动脉疾病进展、斑块不稳定及支架植入后不良事件中的作用。文章指出,除经典炎症外,实验与临床证据提示过敏性炎症效应细胞在冠脉疾病发病和支架植入后事件中具有重要但常被忽视的作用,并讨论了针对过敏性炎症激活特定通路的潜在治疗策略。
要点
- 过敏性炎症效应细胞参与冠状动脉疾病进展与斑块不稳定。
- 过敏性炎症效应细胞参与支架植入后不良事件(支架血栓和再狭窄)。
- 靶向过敏性炎症特定通路可能成为治疗策略。
核心结论
- 过敏性炎症效应细胞在冠状动脉疾病发病、进展、斑块不稳定及支架植入后不良事件中具有重要但常被忽视的作用。
研究设计与样本
- 综述,基于实验与临床研究证据,讨论过敏性炎症效应细胞在冠状动脉疾病和支架植入后事件中的作用及治疗策略。
主要发现
- 过敏性炎症效应细胞参与冠状动脉疾病进展和斑块不稳定。
- 过敏性炎症效应细胞参与支架植入后不良事件,包括支架血栓和支架内再狭窄。
临床怎么用
- 提示临床关注过敏性炎症通路作为冠状动脉疾病及支架植入后事件的潜在治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammation is an important player both for the initiation and progression of coronary artery disease and for coronary plaque instability. Moreover, inflammation contributes to stent thrombosis and in-stent restenosis after percutaneous coronary intervention. In the past several decades, most studies evaluated the involvement of cellular effectors of classic inflammatory responses, such as monocytes/macrophages, neutrophils, and T cells. Yet, besides classic inflammation, mounting evidence derived from both experimental and clinical studies suggests an important, often unrecognized, role for effector cells of allergic inflammation in both the pathogenesis of coronary artery disease and adverse events following stent implantation. In this review, we discuss the role of effector cells of allergic inflammation in the setting of coronary artery disease progression and instability, and in the occurrence of adverse events following stent implantation, as well. Moreover, we discuss possible therapeutic approaches targeting different specific pathways of allergic inflammatory activation.
引用
- Niccoli G, Montone RA, Sabato V, et al. Role of Allergic Inflammatory Cells in Coronary Artery Disease. Circulation. 2018. PMID: 30354461. doi:10.1161/CIRCULATIONAHA.118.035400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。